05Sep 2014
bone logo

Bone. 2014 Sep;66:146-54

These results demonstrate that RANKL produced by osteocytes contributes to the increased bone resorption and the bone loss caused by secondary hyperparathyroidism, strengthening the evidence that osteocytes are an important target cell for hormonal control of bone remodeling

Autor: Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O’Brien CA.
04Sep 2014
bone logo

Bone. 2014 Jun 14;66C:105-110. doi: 10.1016/j.bone.2014.06.008. [Epub ahead of print].

The femorotibial angle (FTA) of the patients with atypical diaphyseal femoral fracture were significantly larger compared to that of those with not only atypical subtrochanteric fractures (AFFs) but also typical femoral fractures (TFFs). In conclusion, the fracture sites of AFFs are associated with the standing lower limb alignment, while those of TFFs are not.

Autor: Saita Y, Ishijima M, Mogami A, Kubota M, Baba T, Kaketa T, Nagao M, Sakamoto Y,
04Sep 2014
bone logo

Bone 2014;66:147-154

The results demonstrate that RANKL produced by osteocytes contributes to the increased bone resorption and the bone loss caused by secondary hyperparathyroidism, strengthening the evidence that osteocytes are an important target cell for hormonal control of bone remodeling.

Autor: Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O’Brien CA.
05Ago 2014
Springer

Calcif Tissue Int. 2014 Nov;95(5):385-92. doi: 10.1007/s00223-014-9904-1. Epub 2014 Aug 27.

While changes in the mode of presentation of PDB have occurred over recent years, many patients present with complications such as fracture and deformity. Further research is required to determine if early detection and therapeutic intervention might be of value in preventing the morbidity associated with this common disease.

Autor: Tan A, Ralston SH.
05Ago 2014
endocrine society

J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9. doi: 10.1210/jc.2014-1413. Epub 2014 Aug 27.

In view of new findings since the last International Workshop on the Management of Asymptomatic PHPT, guidelines for management have been revised. The revised guidelines include: 1) recommendations for more extensive evaluation of the skeletal and renal systems; 2) skeletal and/or renal involvement as determined by further evaluation to become part of the guidelines for surgery; and 3) more specific guidelines for monitoring those who do not meet guidelines for parathyroid surgery. These guidelines should help endocrinologists and surgeons caring for patients with PHPT. A blueprint for future research is proposed to foster additional investigation into issues that remain uncertain or controversial.

Autor: Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr
05Ago 2014
endocrine society

J Clin Endocrinol Metab. 2014 Oct;99(10):3607-18. doi: 10.1210/jc.2014-1417. Epub 2014 Aug 27

The recommended calcium intake in patients with PHPT should follow guidelines established for all individuals. It is not recommended to limit calcium intake in patients with PHPT who do not undergo surgery. Patients with low serum 25-hydroxyvitamin D should be repleted with doses of vitamin D aiming to bring serum 25-hydroxyvitamin D levels to ≥ 50 nmol/L (20 ng/mL) at a minimum, but a goal of ≥75 nmol/L (30 ng/mL) also is reasonable. Pharmacological approaches are available and should be reserved for those patients in whom it is desirable to lower the serum calcium, increase BMD, or both. For the control of hypercalcemia, cinacalcet is the treatment of choice. Cinacalcet reduces serum calcium concentrations to normal in many cases, but has only a modest effect on serum PTH levels. However, bone mineral density (BMD) does not change. To improve BMD, bisphosphonate therapy is recommended. The best evidence is for the use of alendronate, which improves BMD at the lumbar spine without altering the serum calcium concentration. To reduce the serum calcium and improve BMD, combination therapy with both agents is reasonable, but strong evidence for the efficacy of that approach is lacking.

Autor: Marcocci C, Bollerslev J, Khan AA, Shoback DM.
04Ago 2014
bone logo

Bone. 2014 Apr 27;65C:1-8. doi: 10.1016/j.bone.2014.04.023.

In microstructural analysis, alendronate suppressed OVX-induced increase in femoral mid-shaft osteonal bone formation rate (BFR) to a level below that recorded in the sham group, whereas ONO-5334 (Catepsin K inhibitor) at 30mg/kg did not suppress periosteal, osteonal and endocortical BFR. This finding supports the significant effect of ONO-5334 on cortical BMD and mechanical strength in the femoral neck. The results of this study suggest that ONO-5334 has good therapeutic potential for the treatment of osteoporosis.

Autor: Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A,..ect
05Jul 2014
Springer

Osteoporos Int. 2014 Nov;25(11):2609-15. doi: 10.1007/s00198-014-2801-7. Epub 2014 Jul 29.

The study demonstrates that mild or wedged vertebral shape changes are rare among younger subjects, suggesting that when these radiographic abnormalities are seen among older adults, they are less likely to be due to normal variation in vertebral body shape or congenital deformities. In light of previously described associations between mild or wedge vertebral shape changes and low BMD, our findings support current recommendations to treat mild wedged vertebral changes as osteoporosis or at least to consider it as a risk factor for osteoporotic fracture.

Autor: YU W, LIN Q, ZHOU X, SHAO H, SUN P.
05Jul 2014
Springer

Osteoporos Int 2014; Oct;25(10):2453-63. doi: 10.1007/s00198-014-2779-1. Epub 2014 Jul 16

The combination of cytokines present in serum of RA patients with active disease might contribute to bone loss by directly inhibiting osteoblast proliferation and differentiation, but especially by enhancing endogenous cyto- kine (i.e., RANKL and IL-6) production by osteoblasts, there- by stimulating osteoclastogenesis.

Autor: Pathak J L, Bravenboer N, Verschueren P , Lems WF, Luyten F P, Klein-Nulend J, Bakker A D.
05Jul 2014
wiley-logo

J Bone Miner Res. 2014; 29: 1715‒1717. doi: 10.1002/jbmr.2175.

In conclusion, this study profiled serum miRNAs in osteoporosis and identified 9 miRNAs highly associated with osteoporosis in blood serum. In bone tissue, 6 differentially expressed miRNAs were detectable. Five of these were simultaneously upregulated in the serum samples. Those 5 identified, significantly upregulated circulating miRNAs may provide novel biomarkers for osteoporosis and may play an important role in the pathogenesis of osteoporosisrelated hip fractures

Autor: Seeliger C*, Karpinski K , Haug A , Vester H , Schmitt A , Bauer JA and van Griensven M